CAS 136470-79-6: (1R,4S)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol

ent-Abacavir, enantiomer of an anti-HIV carbocyclic nucleoside RT inhibitor, is metabolized in the liver, forms active CBV-TP.

Impurity Abacavir EP Impurity A Applications ent-Abacavir (Abacavir EP Impurity A) is an enatiomer of Abacavir (A105000). Abacavir is a carbocyclic 2'-deoxyguanosine nucleoside reverse transcriptase inhibitor and an anti-HIV drug used to treat HIV infection (1). Intracellular enzymes convert Abacavir to its active form, carbovir-triphosphate (CBV-TP), which then selectively inhibits HIV reverse transcriptase by incorporating into viral DNA (2). Abacavir is metabolized in the liver by uridine diphosphate glucuronyltransferase and alcohol dehydrogenase resulting in inactive glucuronide and carboxylate metabolites, respectively. References (1) Jackson, A., et al.: Antivir Ther. 17, 19 (2012) (2) Yuen, G. J., et al.: Clin Pharmacokinet. 47, 351 (2008)

Ent-abacavir is a drug that belongs to the group of antiretroviral drugs. It has minimal toxicity and has been shown to be effective in long-term treatment of HIV/AIDS. Ent-abacavir is also used as part of active antiretroviral therapy, which includes at least three or four different drugs. It inhibits the activity of reverse transcriptase, an enzyme involved in the replication process of HIV and other retroviruses. This drug has been shown to have few drug interactions with other medications, although caution should be taken when using ent-abacavir with drugs that are metabolized by cytochrome P450 enzymes. Ent-abacavir is not recommended for use in patients who have chronic viral hepatitis or who have a body mass index greater than 30 kg/m2 because its pharmacokinetic properties may be altered in these individuals.